Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
{ "C7R.CD30.CAR-EBVST Cells for CD30-Positive Lymphomas", "This study is for people aged 12 to 75 with CD30-positive lymphomas, including Hodgkin lymphoma and certain T-cell lymphomas, whose disease has returned or not responded to previous treatments. You would receive an intravenous (IV) infusion of C7R.CD30.CAR-EBVST cells, which are special immune cells designed to target and kill cancer cells that have a protein called CD30. Before treatment, you will have tests to confirm your CD30 status and find the best cell match. The main goal is to find a safe dose of C7R.CD30.CAR-EBVST cells, which will be assessed by looking for dose-limiting toxicities (side effects that prevent increasing the dose) within 28 days of treatment. This study aims to see if this treatment is safe and if it can help patients with these types of lymphoma.", "design": "This is a Phase 1 dose-escalation study with an estimated enrollment of 90 participants. Participants are treated in sequential groups, starting with a low dose that is increased in later groups if found safe.", "commitments": "You will undergo screening tests, including lab work and imaging, and may receive chemotherapy before a single intravenous infusion of the study cells. You will be monitored for side effects for at least 28 days.", "compensation": "Not stated in the trial record.", "follow_up": "The primary endpoint for safety is measured at 28 days after treatment.", }
- Study design
- Not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Premal Lulla, MD · PRINCIPAL_INVESTIGATOR · Baylor College of Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Dose Limiting Toxicity (DLT)28 days
Dose-limiting toxicity (DLT) is defined as any of the following considered possibly, probably, or definitely related to study cellular products: (1) Grade 5 event without disease progression; (2) CRS: Grade 4, or Grade 3 not improving to ≤Grade 2 within 72 hours despite therapy; (3) ICANS: Grade 4, or Grade 3 not improving within 72 hours despite therapy; (4) Grade ≥3 IEC-HS; (5) Grade ≥3 acute GvHD requiring corticosteroids and not resolving within 7 days, or steroid-refractory Grade 2 GvHD; (6) Grade 4 neutropenia or thrombocytopenia not resolving to ≤Grade 2 within 42 days, or Grade 3 thrombocytopenia with major bleeding; (7) Grade ≥3 vital organ toxicity (except transient hepatic/renal abnormalities resolving within 7 days); (8) other Grade 3 toxicities not resolving within 72 hours; (9) Grade ≥2 allergic reaction.